Biospherics.net
Biospherics.net Inc. is a scientific research company launched in 2013, focused on biological and pharmaceutical research as well as information technology. Its mission is to create and grow shareholder value through innovations that benefit clients and improve the human condition. The company develops drugs for treating orphan diseases, especially pediatric rare diseases and tropical diseases, including Prader Willi Syndrome, Ebola, Chikungunya virus infections, and ADHD in Fragile X Syndrome. It has ongoing studies for COVID-19 and other treatments.
Industries
Nr. of Employees
small (1-50)
Products
Therapeutic candidate for Prader-Willi syndrome (orphan-designated; completed Phase 2 and Phase 3)
A development-stage therapeutic candidate intended for treatment of Prader-Willi syndrome; completed Phase 2 and Phase 3 clinical studies and holds an FDA orphan drug designation.
Therapeutic candidate developed for Ebola and investigated for COVID-19
A therapeutic candidate originally developed against Ebola virus that has been investigated in studies for activity against SARS-CoV-2.
Therapeutic candidate for Chikungunya virus infection
A development-stage therapeutic candidate targeting Chikungunya virus infection.
Therapeutic candidate for abdominal aortic aneurysms (AAA)
A development-stage therapeutic candidate under testing for treatment of abdominal aortic aneurysms.
Drug-device combination therapy for ADHD in Fragile X syndrome
A combined therapeutic and device approach designed to treat attention-deficit symptoms in patients with Fragile X syndrome.
Therapeutic candidate for Prader-Willi syndrome (orphan-designated; completed Phase 2 and Phase 3)
A development-stage therapeutic candidate intended for treatment of Prader-Willi syndrome; completed Phase 2 and Phase 3 clinical studies and holds an FDA orphan drug designation.
Therapeutic candidate developed for Ebola and investigated for COVID-19
A therapeutic candidate originally developed against Ebola virus that has been investigated in studies for activity against SARS-CoV-2.
Therapeutic candidate for Chikungunya virus infection
A development-stage therapeutic candidate targeting Chikungunya virus infection.
Therapeutic candidate for abdominal aortic aneurysms (AAA)
A development-stage therapeutic candidate under testing for treatment of abdominal aortic aneurysms.
Drug-device combination therapy for ADHD in Fragile X syndrome
A combined therapeutic and device approach designed to treat attention-deficit symptoms in patients with Fragile X syndrome.
Services
In silico pathway modeling and computational biology support for therapeutic candidate identification and optimization.
In silico pathway modeling and computational biology support for therapeutic candidate identification and optimization.
Expertise Areas
- Orphan drug development
- Pediatric rare disease therapeutics
- Tropical infectious disease therapeutics
- Antiviral therapeutic investigation and repurposing
Key Technologies
- Computational biology
- Pathway simulation
- In silico drug design and modeling
- Clinical trial design and execution
News & Updates
Biospherics.net completed Phase 2 and Phase 3 clinical trials of BSN175, which has received FDA orphan drug designation.
The company is developing drugs for Prader Willi Syndrome, Ebola, Chikungunya, and other conditions, including studies on BSN389 for COVID-19.
Biospherics.net completed Phase 2 and Phase 3 clinical trials of BSN175, which has received FDA orphan drug designation.
The company is developing drugs for Prader Willi Syndrome, Ebola, Chikungunya, and other conditions, including studies on BSN389 for COVID-19.